Suppression of Early TNF-Alpha Increase by a Single Evolocumab Dose in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention
Journal of Clinical Medicine · 23.06.2026 · 15 (13) · 4873
DOI: 10.3390/jcm15134873 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 23.06.2026. Verfasst von Giuseppe Patti und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medicine, University of Eastern Piedmont, Via Solaroli 17, 28100 Novara, Italy. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Early initiation of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9-i) in patients with acute myocardial infarction (MI) may anticipate and maximize lipid-lowering benefit. Whether PCSK9 inhibition also exerts early anti-inflammatory effects in this setting remains unclear. This study aimed to evaluate the effects of early PCSK9-i administration on inflammatory markers and lipid parameters in patients with acute MI undergoing percutaneous coronary intervention (PCI).
Methods
In this randomized, prospective, single-center, open-label trial, patients with acute MI undergoing PCI were randomly assigned to receive a single upstream 140 mg subcutaneous dose of evolocumab immediately before PCI, on top of oral lipid-lowering therapy (LLT) (n = 30), or oral LLT alone (control group; n = 30). Tumor necrosis factor-alpha (TNF-α), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (apoB), and lipoprotein(a) [Lp(a)] levels were measured at baseline and during the early post-intervention phase.
Results
Baseline TNF-α values and lipid parameters were similar between the two groups. At 72 h after PCI, TNF-α levels were significantly lower in the evolocumab arm compared with controls (0.01 vs. 0.25 pg/mL; p = 0.025). Evolocumab was also associated with a greater relative reduction in LDL-C levels from baseline (−48% vs. −18%; p < 0.001) and apoB levels (−34% vs. −11%; p < 0.001). The proportion of patients achieving the LDL-C goal of
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Translational Medicine, University of Eastern Piedmont, Via Solaroli 17, 28100 Novara, Italy.
- Division of Cardiology, Maggiore della Carità Hospital, 28100 Novara, Italy.
ORCID-Profile: Giuseppe Patti, Alessandra Marengo, Luca Cumitini, Leonardo Grisafi, Marco Mennuni
Zitieren
APA
Patti, G., Bosco, M., Marengo, A., Cumitini, L., Grisafi, L., D'Amario, D., Solli, M., & Mennuni, M. (2026). Suppression of Early TNF-Alpha Increase by a Single Evolocumab Dose in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Journal of Clinical Medicine, 15(13), 4873. https://doi.org/10.3390/jcm15134873
Vancouver
Patti G, Bosco M, Marengo A, Cumitini L, Grisafi L, D'Amario D, et al. Suppression of Early TNF-Alpha Increase by a Single Evolocumab Dose in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Journal of Clinical Medicine. 2026;15(13):4873. doi:10.3390/jcm15134873
BibTeX
@article{Patti2026,
author = {Patti, Giuseppe and Bosco, Manuel and Marengo, Alessandra and Cumitini, Luca and Grisafi, Leonardo and D'Amario, Domenico and Solli, Martina and Mennuni, Marco},
title = {Suppression of Early TNF-Alpha Increase by a Single Evolocumab Dose in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {13},
pages = {4873},
doi = {10.3390/jcm15134873}
}
EUVIMED